Why Takeda Pharmaceutical Co ADR (NYSE: TAK) At $13.15 Is Worth Your Money?

Takeda Pharmaceutical Co ADR (NYSE:TAK) does about 1.52M shares in volume on a normal day but saw 942735 shares change hands in the recent trading day. The company now has a market cap of 41.27B USD. Its current market price is $13.15, marking a decrease of -0.23% compared to the previous close of $13.18. The 52 week high reached by this stock is $16.39 whilst the lowest price level in 52 weeks is $12.57.

Takeda Pharmaceutical Co ADR (TAK) has a 20-day trading average at $13.04 and the current price is -19.77% off the 52-week high compared with 4.57% distance from its 52-week low. The 50-day simple moving average of the closing price is $13.16 and its 200-day simple moving average is $14.02. If we look at the stock’s price movements over the week, volatility stands at 0.74%, which increases to 0.95% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 52.32 to suggest the stock is neutral.

The consensus objective for the share price is $15.23, suggesting that the stock has a potential upside of 13.66% over the period.

2 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on March 16, 2023 when BofA Securities upgraded the stock to “Buy” and issued a price target of $20. Cowen also upgraded the stock to “Outperform” from Market Perform on July 19, 2022 at a price target of $21-$24.

Takeda Pharmaceutical Co ADR (TAK) stock is up 1.15% over the week and -2.81% over the past month. Its price is -7.85% year-to-date and -15.05% over the past year.

To reach the target analysts have set, the stock logically needs to grow 13.66 percent from here.

The company has a return on investment of 1.25% and return on equity of 2.11%. The price to earnings ratio (P/E ratio) amounts to 41.03 while the forward price to earnings ratio is 32.16. The beta has a value of 0.58. Price to book ratio is 0.86 and price to sales ratio is 1.40.